RE: Sulforaphane - SFX-012 Dec 2022 09:33
Results and moving forward:
Evgen has licensed the global rights for lead asset SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla.
Stalicla will use its proprietary precision medicine platform to identify specific phenotypes of autism spectrum disorder (ASD). Evgen and Stalicla will collaborate initially on a clinical programme in ASD, with Stalicla funding all clinical development activities.
Evgen retains the global rights for all other indications.
Evgen has licensed Sulforadex®, its sulforaphane stabilisation technology, in a number of non-pharmaceutical applications to Juvenescence Ltd.
Juvenescence will deploy the Sulforadex® stabilisation technology to manufacture and market a nutritional health product containing a defined and stable dose of naturally derived sulforaphane. Launch is expected within the next two years.
Milestone payments along 2023 and expect rerating along towards market cap towards £50m IMO